Long-term TNF-alpha therapy for preserving beta cell function in new onset type 1 diabetes: a case report
Our patient's improvement in glycaemic control can be explained by immunomodulation and C peptide preservation from infliximab. With the growing focus on type 1 diabetes disease modulation and working towards an 'insulin free T1D', our findings strengthen the evidence base for the repurposing of and long-term treatment with anti-TNF-α agents to preserve beta-cell function in new onset T1D.
Authors
- Lauren M. Quinn (ORCID: https://orcid.org/0000-0003-0500-4417)
- Adya Rao (ORCID: https://orcid.org/0000-0003-2181-5180)
- Parth Narendran (ORCID: https://orcid.org/0000-0002-4583-8793)
Institutions
- Queen Elizabeth Hospital Birmingham (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- Clinical Diabetes and Endocrinology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s40842-024-00185-6
- Citations
- 5
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.75